Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hügli, A.
Right arrow Articles by Bonnefoi, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hügli, A.
Right arrow Articles by Bonnefoi, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 11:1557-1561, 2000
© 2000 European Society for Medical Oncology

research-article

Infusional ECarboF in patients with advanced breast cancer: A very active and well-tolerated out-patient regimen

A. Hügli1,, A.-P. Sappino1, S. Anchisi3, B. Mermillod4, P. Schafer2, J. L. Anguenot2 and H. Bonnefoi2

1Division d'Oncologie, Hôpital Cantonal Universitaire de Genève Switzerland
2Département de Gynécologie-Obstétrique, Hôpital Cantonal Universitaire de Genève Switzerland
3Service d'Oncologie, Hôpital Régional de Sion Switzerland
4Division d'Informatique Médicale, Hôpital Cantonal Universitaire de Genève Switzerland

Correspondence to: A. Hugli, MD, Division d'Oncologie Hôpital Cantonal de Genève 24 av Micheli-du-Crest 1211 Genève 14 Switzerland E-mail: Anne.Huegli{at}hcuge.ch

We performed a trial using the combination of epirubicin 50 mg/m2/day 1, carboplatinum AUC 5/day 1 and continuous 5-fluorouracil (5-FU) 200 mg/m2/day (every 4 weeks for 6 months) to confirm the efficacy and low toxicity profile of this regimen in breast cancer. In 51 patients with metastatic (n = 33) or locally advanced (n=18) breast cancer the overall response rate was 86% (95% confidence interval (95% CI): 73%–94%): 94% in locally advanced and 81% metastatic disease. Grade 3–4 toxicity was low: 4% of patients presented with febrile neutropenia, 16% with severe palmar-plantar syndrome, 10% with Port-a-cath thrombosis.

This study confirms the high efficacy of infusional 5-FU-based regimens and justifies further research into novel promising oral 5-FU derivatives.

breast cancer, carboplatinum, chemotherapy, continuous 5-fluorouracil


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.